Clinical trials: Immunocompromised
Human Papilloma Virus Infection
Immunogenicity of 9-valent HPV Vaccine
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately…
- Trial name
- NCT05439083
- Testing
- 9-valent HPV vaccine
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Talia Sainz Costa
Influenza
Influenza Vaccine in Pediatric Transplant Subjects
The purpose of this study is to evaluate how well children responds to the recommended trivalent subviron influenza vaccine (flu shot).
- Trial name
- NCT00133510
- Testing
- Trivalent Subviron Influenza vaccine (Fluzone)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant, Immunology
Protective Immunity Project 02
Influenza (Flu) vaccine is recommended for kidney transplant patients who are at least 6 months post-transplant. The influenza vaccine stimulates the immune system to builds protective antibodies against the flu virus.
- Conditions
- Kidney Transplant, Immunology, Immunosuppression
- Trial name
- PIP-02 (NCT00833651)
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Emory University
Tuberculosis
Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients
For diagnosis of active tuberculosis, interferon-γ release assay based mycobacterium tuberculosis specific antigen may show higher sensitivity than tuberculin skin test in immunocompromised patients.
- Trial name
- NCT00962676
- Where
- South Korea
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Covid19, Rheumatic Diseases
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases
This study will evaluate the Moderna RNA-based COVID-19 vaccine currently approved by Health Canada in people with rheumatic diseases.
- Conditions
- Covid19, Rheumatic Diseases, Rheumatoid Arthritis, SLE
- Trial name
- COVIAAD (NCT04806113)
- Testing
- Moderna COVID-19 vaccine
- Where
- Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Immunocompromised
H1N1sw Vaccine in Adult Transplant Recipients
The trial investigates the efficacy of the adjuvanted H1N1 influenza vaccine Focetria(R) in immunocompromised adults who have undergone solid organ or bone marrow transplantation.
- Trial name
- NCT01069601
- Testing
- Focetria (2x H1N1 vaccine with MF59 adjuvants)
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- HepNet Study House, German Liverfoundation
Tuberculosis, Monitoring, Immunologic
T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals
Until recently, the tuberculin skin test (TST) was the only available diagnostic assay for detection of latent infection with M. tuberculosis (LTBI).
- Trial name
- TBNET-TIPS (NCT00707317)
- Where
- 21 sites in Australia, Bulgaria and 12 more
- Volunteers
- 1,843 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Network European Trialsgroup
Covid19, Haematological Disorders
Covid-19 Vaccine Response in Immunocompromised Haematology Patients
The UK Medicine and Healthcare products Regulatory Agency (MHRA) granted temporary authorisation to three Covid-19 vaccines in December 2020 and January 2021.
- Conditions
- Covid19, Haematological Disorders, Immune Suppression
- Trial name
- COVAC-IC (NCT04805216)
- Testing
- Blood test
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Meningococcal Vaccine
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
The aim of this study is to evaluate the safety, tolerability, and immunogenicity of 2 doses of Trumenba® (on a 0- and 6-month schedule) in immunocompromised participants by functionally assessing antibody production in asplenic…
- Trial name
- NCT04893811
- Testing
- Trumenba
- Where
- 14 sites in Czechia, Poland and 1 more
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rabies Exposure, Immunocompromised
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients…
- Conditions
- Rabies Exposure, Immunocompromised, Chronic Disease
- Trial name
- NCT07120464
- Testing
- Observation Only
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Covid19
COVID-19 Vaccination of Immunodeficient Persons (COVAXID)
The study is designed as an open, non-randomized, phase IV cohort study in which the mRNA vaccine Comirnaty will be given in two doses.
- Trial name
- COVAXID (NCT04780659)
- Testing
- Comirnaty (COVID-19, mRNA vaccine)
- Where
- Sweden
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Covid19, COVID-19 Vaccines
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
Despite COVID-19 pandemic having started more than one year ago, there are still limited treatment options for these patients, and over 145 million cases and 3 millions deaths have ensued worldwide.
- Trial name
- NCT04888793
- Testing
- Serologic immune response evaluation
- Where
- Chile
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Focus: Immunocompromised Individuals at High Risk of Aqcuiring Invasive Aspergillosis
Diagnostic Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples
Multicentre, diagnostic study evaluating the performance of an aspergillus-specific PCR in cerebrospinal fluid samples of immunocompromised patients for identification of central nervous system aspergillosis.
- Trial name
- NCT01614145
- Where
- 3 sites in Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Invasive Aspergillosis, Acute Leukemia
Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients
The aim of our prospective and multicentre diagnostic study is therefore to elucidate on the sensitivity and specificity rates of these serologic markers in combination with molecular tools (both an Aspergillus specific and a…
- Conditions
- Invasive Aspergillosis, Acute Leukemia, Biomarkers, Stem Cell Transplantation
- Trial name
- NCT01695512
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
HIV Seropositivity, Immunodeficiency
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
The aim of this study is to identify both the humoral immunological response through the detection of induced antibodies and the cellular immunological response through the detection of interferon gamma production by functional…
- Conditions
- HIV Seropositivity, Immunodeficiency, Vaccination Reaction, Covid19
- Trial name
- NCT05672654
- Testing
- Blood draw
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Hematological Malignancies, Cancer
Cologne Cohort of Neutropenic Patients (CoCoNut)
The Cologne Cohort of Neutropenic Patients (CoCoNut) is a non-interventional cohort study assessing risk factors, interventions, and outcome of immunosuppressed patients with or without opportunistic infections.
- Conditions
- Hematological Malignancies, Cancer, Chemotherapy, Neutropenia
- Trial name
- CoCoNut (NCT01821456)
- Testing
- Antiinfectives
- Where
- Germany
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- University Hospital of Cologne
Infections, Meningococcal
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new meningococcal vaccine 134612 in subjects with increased risk of meningococcal disease and compare it to its activity in healthy…
- Trial name
- NCT01641042
- Testing
- Meningococcal vaccine GSK134612
- Where
- 16 sites in United States, Czechia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement…
- Trial name
- NCT02141516
- Testing
- rMenB+OMV
- Where
- 20 sites in Italy, Poland and 3 more
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Novartis
Respiratory Syncytial Virus (RSV)
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems.
- Trial name
- STRIVE (NCT07050732)
- Testing
- Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total)
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)